Champions Oncology (CSBR) Research & Development (2010 - 2026)

Champions Oncology has reported Research & Development for 17 years, with the latest figure at $2.3 million in Q2 2026.

• On a quarterly basis, Research & Development rose 1.73% year-over-year to $2.3 million in Q2 2026; TTM through Apr 2026 was $9.7 million, a 28.73% increase from a year earlier, with the FY2026 full-year figure at $9.3 million, up 23.5% from the prior year.
• Research & Development was $2.3 million for Q2 2026 at Champions Oncology, down from $2.7 million in the prior quarter.
• The five-year high for Research & Development was $3.2 million in Q1 2023, with the low at $1.7 million in Q3 2024.
• Average Research & Development over 5 years is $2.4 million, with a median of $2.4 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Research & Development slumped 39.89% in 2024, then jumped 49.4% in 2025.
• Over 5 years, Research & Development stood at $2.6 million in 2022, then retreated by 3.42% to $2.5 million in 2023, then slumped by 30.38% to $1.8 million in 2024, then surged by 49.4% to $2.6 million in 2025, then slipped by 10.21% to $2.3 million in 2026.
• The last three Research & Development figures came in at $2.3 million (Q2 2026), $2.7 million (Q1 2026), and $2.6 million (Q4 2025), per Business Quant data.